Co-Promotion of a New Medical Device for Female Infertility AnnouncedBy Norgenix Pharmaceuticals Llc, PRNE
Monday, January 17, 2011
SPARTANBURG, South Carolina, January 18, 2011 - Norgenix Pharmaceuticals, LLC (www.norgenixpharma.com), a wholly
owned subsidiary of Spartanburg-based J M Smith Corporation, and Fertility
Focus Limited (www.fertility-focus.com) today announced a partnership
for the co-promotion of the Fertiloscope(TM), a CE marked and 510(k) approved
surgical instrument for the early diagnosis and immediate corrective surgery
of physical causes of female infertility. Norgenix has exclusive rights to
market and distribute the Fertiloscope(TM) in the United States, as well as
US territories and military bases. The product will benefit from the
strategic support of Glenveigh Medical (www.glenveigh.com) as well,
with whom Norgenix has an existing alliance in the U.S. to promote medical
devices developed by Glenveigh.
Norgenix and Fertility Focus also announced a strategic alliance and
revealed its first medical device co-promotion, the Fertiloscope(TM).
Norgenix is a North American specialty pharmaceutical, medical device and
biotechnology company that engages in the development, commercialization, and
sales of products in the women's health arena. Norgenix is licensed to sell,
market, and distribute prescription drug products and medical devices in all
50 U.S. states. Fertility Focus is a United Kingdom based company that
develops devices aimed at the infertility market.
Developed by the eminent French surgeon Dr. Antoine Watrelot, the
Fertiloscope(TM), is a novel laparoscope for minimally invasive trans-vaginal
use in a procedure that is known as Fertiloscopy. The Fertiloscope(TM) is the
only method of primary screening that provides gold standard accuracy in a
day-case or office setting. This relatively new surgical technique is used
for the early diagnosis and immediate treatment of a number of disorders of
the female reproductive organs.
Norgenix is dedicated to in-licensing product opportunities and building
strategic alliances with companies interested in maximizing the value of
products that fulfill unmet medical needs in the U.S. marketplace. As a
strategic partner, Norgenix and the related J M Smith partner companies will
provide strategic direction and capitalization to build success.
MEDIA CONTACT: Sims Hammond +1-864-580-2350 Sims@LaunchSomething.com
Sims Hammond, +1-864-580-2350, Sims at LaunchSomething.com
Tags: January 18, Norgenix Pharmaceuticals Llc, South Carolina, Spartanburg